Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)

被引：0
|
作者：
Fabi, Alessandra
Carbognin, Luisa
Botticelli, Andrea
Paris, Ida
Fuso, Paola
Savastano, Maria Cristina
La Verde, Nicla
Strina, Carla
Pedersini, Rebecca
Guarino, Stefania
Curigliano, Giuseppe
Criscitiello, Carmen
Raffaele, Mimma
Beano, Alessandra
Franco, Antonio
Valerio, Maria Rosaria
Verderame, Francesco
Fontana, Andrea
Haspinger, Eva Regina
Caldara, Alessia
Di Leone, Alba
Tortora, Giampaolo
Giannarelli, Diana
Scambia, Giovanni
机构：
[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology
[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health
[3] University of Rome,Medical Oncology Unit, La Sapienza
[4] Medical Oncology Unit,Department of Oncology and Hemato
[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology
[6] Medical Oncology Unit,Department of Medical Oncology1
[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences
[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery
[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility
[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined
[11] University of Milan,undefined
[12] Division of Early Drug Development,undefined
[13] European Institute of Oncology,undefined
[14] IRCCS,undefined
[15] Presidio Cassia Sant’andrea,undefined
[16] Dipartimento Oncologico,undefined
[17] Asl Roma1,undefined
[18] Città della Salute e della Scienza Hospital,undefined
[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined
[20] Medical Oncology,undefined
[21] Policlinico Universitario P. Giaccone,undefined
[22] Medical Oncology,undefined
[23] AO Riuniti Villa Sofia,undefined
[24] Cervello,undefined
[25] Medical Oncology Unit 2,undefined
[26] Azienda Ospedaliero-Universitaria Pisana,undefined
[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined
[28] Santa Chiara Hospital,undefined
[29] Medical Oncology,undefined
[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[31] Università Cattolica del Sacro Cuore,undefined
[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[33] Università Cattolica del Sacro Cuore,undefined
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
D O I：
10.1038/s41523-024-00619-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 983 - 993
  • [22] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
    Brufsky, Adam
    Kim, Sung-Bae
    Zvirbule, Zanete
    Dirix, Luc Yves
    Eniu, Alexandru E.
    Carabantes, Francisco
    Izarzugaza, Yann
    Mebis, Jeroen
    Sohn, Joohyuk
    Wongchenko, Matthew
    Chohan, Saibah
    Amin, Reena
    McNally, V. A.
    Miles, David
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1245 - 1247
  • [24] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumi
    Tamura, Kenji
    Armstrong, Anne
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Card, Deborah
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience
    Waterhouse, Jasmin V.
    Holdich, Alexandra
    Mina, Florentia
    Obeid, Mariam
    Joshi, Kroopa
    Barrett, Sophie
    Rajakumar, Lavarniya
    McCormick, Gemma
    Seymour, Sally
    Koliou, Panagiotis
    Sylva, Rushan
    Ayodele, Olubukola
    Gautam, Ashram
    Smith, Jenny
    McKeon, Jenny
    Strawson-Smith, Thomas
    Douglas, Rosalie
    Borley, Annabel
    Konstantis, Apostolos
    McGrath, Sophie
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
    Schmid, Peter
    Loirat, Delphine
    Savas, Peter
    Espinosa, Enrique
    Boni, Valentina
    Italiano, Antoine
    White, Shane
    Singel, Stina M.
    Withana, Nimali
    Mani, Aruna
    Li, Suwen
    Harris, Adam
    Wongchenko, Matthew
    Sablin, Marie
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Real-world analysis of taxane use in the first-line setting and prior comorbidities among female metastatic triple-negative breast cancer patients
    Lin, Shih-Wen
    Thakrar, Dixa
    Simpson, Joseph
    Funke, Roel
    Chui, Stephen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 97 - 98
  • [29] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [30] Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
    Schmid, P.
    Kuemmel, S.
    Loirat, D.
    Savas, P.
    Espinosa, E.
    Boni, V
    Italiano, A.
    White, S.
    Singel, S.
    Withana, N.
    Mani, A.
    Li, S.
    Harris, A.
    Wongchenko, M.
    Sablin, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E44 - E45
12345